? ADMINISTRATION CORE Stanford Cancer Institute's (SCI) Administration Core, under the leadership of David Rubenson, MS, MBA, Associate Director of Administration and Planning, supports the SCI mission to provide innovative research, patient care, and education. The core includes 18 employees who contribute administratively to the success of the basic, clinical, and population sciences, as well as to the training and educational mission of the Stanford Cancer Institute. The core provides direct administrative oversight of the Cancer Clinical Trials Office (CCTO), 8 faculty laboratories, 2 shared resources, and other assets. Overall, approximately 200 staff employees report through the administrative core. SCI administration covers: CCSG membership processes, shared resources oversight and support, coordination with SCI's consortium partner the Cancer Prevention Institute of California (CPIC), management of faculty assigned to SCI, oversight and control of SCI financial resources, seed grant administration, grants management, general administration and human resources, support for strategic planning, ESAB activities, and external and internal communications. The administrative core provides active support in planning and implementing scientific conferences and workshops. The core also plays a key role in outreach activities, publishing a quarterly newsletter that reaches more than 10,000 recipients, providing administrative support for a Community Engagement Program, and representing SCI at major events sponsored by outside foundations and advocacy groups. During the current grant period, the SCI administrative unit made the following improvements: 1) an expanded and refined structure that includes dedicated teams for financial analysis and for supporting multi- investigator grant applications including the CCSG; 2) incorporation of the PhD program in Cancer Biology into the administrative structure; 3) an expanded capacity for event planning as exemplified by the October 2014 symposium Tumor Heterogeneity: Implications for Targeted Therapy, attended by ~ 250 researchers; 4) institution of the OnCore Biospeciman Management System (BSM) to insure connectivity between the Cancer Clinical Trials Office (CCTO) and the Tissue Procurement Shared Resource; and 5) support for centralization of all clinical trials personnel within SCI's CCTO. More generally, the administrative core has developed a robust structure that will allow it to accommodate to changing requirements in the years ahead. While individual senior leaders were rated highly at the last review, challenges remained in program integration, monitoring of shared resources, the population sciences, and administration. These issues led Dr. Mitchell to make substantial changes in the senior leadership team. The leaders are now highly interactive and engaged. The senior leadership team is responsible for strategic planning, program integration, and the evaluation of SCI's initiatives in research, clinical care, and training/education. The senior leaders provide oversight for SCI research programs, administration, shared resources, the CCTO, and the Protocol Review and Monitoring System. They are members of a broader executive committee that helps coordinate SCI activities with other activities across the University that could contribute to cancer research. The SCI senior leadership is responsible for coordinating across research domains and defining strategies and opportunities to maximize clinical translation, as well as identifying areas in which SCI research expertise can be deployed to address needs of the catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-10
Application #
9308878
Study Section
Special Emphasis Panel (ZCA1-RTRB-0)
Project Start
Project End
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
10
Fiscal Year
2017
Total Cost
$372,090
Indirect Cost
$136,611
Name
Stanford University
Department
Type
Domestic Higher Education
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Champion, Magali; Brennan, Kevin; Croonenborghs, Tom et al. (2018) Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response. EBioMedicine 27:156-166
Zhou, Mu; Leung, Ann; Echegaray, Sebastian et al. (2018) Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications. Radiology 286:307-315
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366

Showing the most recent 10 out of 322 publications